| AbbVie AG - Skyrizi 150mg, Injektionslösung im Fertigpen |
| 68118 | | 01 | | Skyrizi 150mg | | Injektionslösung im Fertigpen | | L04AC18 | | Risankizumab | | 07.07.2021 | | |
|
| Composition |
| risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. |
| Packungsbestandteile |
| | | | | | | | | Active Agent | Dose |
|---|
| | 150 mg/ml |
| | BAG: Active Agent | Dose |
|---|
| | 150 mg |
| | | | Inactive agents |
|---|
| Acidum Aceticum Glaciale | | Sodium Acetate Trihydrate | | | | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 3085.45 | 3372.05 | B | SL | No |
|
